Weight is a contributing factor to many diseases and health conditions. Many people across the globe are clinically overweight or obese, putting them at risk for several problems.
To overcome obesity, doctors suggest eating healthier and exercising daily. Unfortunately, reducing caloric intake and making dietary changes sufficient for significant weight loss can take time and effort.
That's why many physicians are recommending medication to assist with the process. Glucagon is the main component of these medications.
When used with a healthy lifestyle, medications like Ozempic/Semaglutide are very effective in helping people lose weight.
GLP-1 is a hormone your body produces to reduce your appetite, improve your metabolic function, and increase satiety.
People who are clinically obese or overweight show a decrease in GLP-1 signalling. Research has shown that medications like Ozempic/ Semaglutide can mimic the effect of natural brain signals on the GLP-1 hormones.
Various studies on Ozempic (Semaglutide) show that it is a game-changer for effective weight loss. Semaglutide and Wegovy were recently approved by the European Medicine Agency (EMA) for weight loss and treating obesity. Although Ozempic is currently not licenced for weight loss, it contains the same drug as Wegovy, which is approved and can, therefore, be prescribed to assist you in losing weight.
The first STEP1 study, authored by Professor John Wilding, Professor Rachel Batterham, and other co-authors, was recently published in The New England Journal of Medicine under "Once-Weekly Semaglutide in Adults With Overweight or Obesity."
Throughout a 68-week study, those who received a Semaglutide injection once a week lost about 15% of their body weight compared to those who received a placebo (2.4% weight loss).
The Ozempic, Semgalutide licensed for type II diabetes, is administered considerably lower (maximum one milligram) than the weight drug, Wegovy, used in this study (2.4 milligrams).
The study reveals that when people took Semaglutide and began to make healthy lifestyle changes, they could efficiently and effectively lose weight—a few adverse effects led to some people opting to end treatment. The most frequent side effects associated with Semaglutide are nausea and diarrhoea. These side effects usually occur after the initial dose and can be easily managed with a small dose of Esomeprazole.
The results show that the Semaglutide-taking group lost 15% more weight than the placebo group, which lost only 2.4%
Research proves that Semaglutide injections are beneficial in reducing weight. Overweight people who can take medicine and adopt a healthy lifestyle will lose significant weight.
As the number of adults with Type II Diabetes grows worldwide, researchers are conducting more research to assist people in effectively managing their diabetes. Approximately 90% of individuals with Type II Diabetes are either overweight or obese.
We all know that lowering weight can assist blood sugar management and sometimes eliminate Type II Diabetes. Over the last ten years, new drugs have been produced to help people better manage their condition and improve their health. Medications for diabetes are designed not just to reduce blood glucose levels but also to target weight loss.
This study evaluates a new diabetes cure that is still in the early stages of development, known as Semaglutide. This drug is a GLP-1(Glucagon-Like Peptide-1) metabolite. The commercial/generic names for this medication are Ozempic and Wegovy.
GLP-1 is a naturally occurring hormone that affects glucose and appetite control. Changes in the pancreas and brain regulate blood glucose and hunger. The hormone Glucagon, Peptide, or GLP-1 plays an important role.
GLP-1 stimulates insulin production, which only works when blood glucose is high and does not stimulate insulin production if blood glucose levels are low.
It also inhibits glucagon secretion in response to higher blood glucose levels. Glucagon is a hormone that raises blood sugar levels. When blood glucose levels are low, the pancreas typically produces glucagon.
Glucagon converts the liver's glycogen to glucose. After eating, gastric emptying is momentarily delayed, lowering blood sugar levels. Semaglutide lowers insulin production when blood glucose levels are low.
Beyond this, it can help you lose weight and fat by reducing food consumption and cravings. Ozempic® also decreases the preference for high-fat foods.
Ozempic (or Semaglutide) is a GLP-1 analogue and is given as an injection once a week.
Ozempic was superior at lowering HbA1c (Glycosylated haemoglobin, a measure of blood glucose control) from baseline compared to dulaglutide, exenatide OW, Sitagliptin, and insulin glargine, according to research.
For all comparisons, semaglutide (Ozempic) 1 mg was superior and resulted in more significant weight reduction from baseline than dulaglutide (another GLP-1 analogue), exenatide (weekly), Sitagliptin, and insulin glargine.
Ozempic treatment reduced the chance of dying from cardiovascular causes by 26%, including non-fatal heart attack or non-fatal stroke.
Ozempic, like other GLP-1 analogues, has been found to lower blood pressure and improve plasma lipids.
This means the medication is a glucagon-like peptide taken as an injection. However, only a tiny amount of one milligram is injected once a week.
Different research studies show that Semaglutide or Ozempic is considered a medicine that can reduce the Hemoglobin Glycosylated and is considered superior to all the available drugs on the market.
Semaglutide is superior in weight loss to Sitagliptin and the drugs mentioned above in every study. In addition, it is superior to Insulin Glargine, Dulaglutide, Sitagliptin, and Exenatide OW. 1 milligram of Ozempic is enough for a weight loss of about 15 kg. In contrast, Dulaglutide is taken at 3.5 milligrams and loses only 6.5 kg of body weight.
Ozempic also offers many benefits and helps with the reduction of numerous diseases. For example, when a Type II diabetic patient is treated with Ozempic (Semaglutide) to treat obesity, Ozempic helps reduce the risk of cardiovascular diseases by 26%. In addition, it helps to minimise fatal heart attacks.
At the same time, the glucagon peptide in the Semaglutiide helps reduce blood pressure and maintain the liquid plasma level in the blood.
The use of Semaglutide in persons with diabetes mellitus type I or diabetic ketoacidosis is not recommended. Semaglutide is not a substitute for insulin and should be used alongside it.
Patients with heart failure should not take Semaglutide. The New York Heart Association has classified it as a class IV drug.
The use of GLP-1 receptor agonists has been linked to acute pancreatitis or inflammation of the pancreas. Abdominal discomfort, loss of appetite, nausea and vomiting are symptoms of acute pancreatitis. If pancreatitis is suspected, please immediately visit the closest emergency room.
If you have been diagnosed with pancreatitis, stop taking Semaglutide immediately.
Patients treated with Semaglutide or any GLP-1 analogue in combination with a sulfonylurea or insulin may have an elevated risk of hypoglycemia (low blood glucose levels of less than 4mmol/l or 72mg/dl). When starting treatment with GLP-1 analogue, the risk may be lowered by lowering the dose of sulfonylureas, such as gliclazide or insulin.
When receiving Ozempic, women of childbearing age should use contraception. As a result, Ozempic should not be used during pregnancy because there is no information about its safety.